Jeannette Potts
Compliance Officer bei UNIQURE N.V.
Vermögen: 502 320 $ am 31.03.2024
Profil
Jeannette Potts is currently the Secretary, Senior Vice President & General Counsel at Forma Therapeutics Holdings, Inc. and also holds the position of Chief Legal & Compliance Officer at uniQure NV.
Previously, she worked as the Director-Marketing & Sales at Viroblock SA and as the Associate General Counsel at Millennium Pharmaceuticals, Inc. She was also the VP, Head Counsel-Research & Development at Takeda Pharmaceuticals U.S.A., Inc. from 2013 to 2019.
Dr. Potts holds a doctorate degree from the University of Virginia, an undergraduate degree from Smith College, a graduate degree from Suffolk University, and an undergraduate degree from Trinity College Dublin.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
UNIQURE N.V.
0,20% | 01.03.2024 | 96 600 ( 0,20% ) | 502 320 $ | 31.03.2024 |
Aktive Positionen von Jeannette Potts
Unternehmen | Position | Beginn |
---|---|---|
FORMA THERAPEUTICS HOLDINGS, INC. | General Counsel | 01.09.2019 |
UNIQURE N.V. | Compliance Officer | - |
Ehemalige bekannte Positionen von Jeannette Potts
Unternehmen | Position | Ende |
---|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Chief Tech/Sci/R&D Officer | 01.08.2019 |
Viroblock SA
Viroblock SA Miscellaneous Commercial ServicesCommercial Services Viroblock SA develops and commercializes antiviral products. Viroblock technology uses a novel mechanism of action to inactivate enveloped viruses, human and avian such As influenzas, SARS virus and the AIDS virus. The company was founded by Donald F. H. Wallach in 2005 and is headquartered in Irvine, CA. | Sales & Marketing | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von Jeannette Potts
University of Virginia | Doctorate Degree |
Smith College | Undergraduate Degree |
Suffolk University | Graduate Degree |
Trinity College Dublin | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
UNIQURE N.V. | Health Technology |
Private Unternehmen | 4 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Viroblock SA
Viroblock SA Miscellaneous Commercial ServicesCommercial Services Viroblock SA develops and commercializes antiviral products. Viroblock technology uses a novel mechanism of action to inactivate enveloped viruses, human and avian such As influenzas, SARS virus and the AIDS virus. The company was founded by Donald F. H. Wallach in 2005 and is headquartered in Irvine, CA. | Commercial Services |
Forma Therapeutics Holdings, Inc.
Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |